<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Aimmune Therapeutics, Inc.

    Aimmune Therapeutics, Inc.

    Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical c...

    Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a...

    Filing Type:    PU
    Stoke Therapeutics, Inc.

    Stoke Therapeutics, Inc.

    Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...

    Stoke is pioneering a new way to treat the unde...

    Filing Type:    PU
    Morphic Holding, Inc.

    Morphic Holding, Inc.

    Morphic Therapeutic is leading the development of a new generation of oral integri...

    Morphic Therapeutic is leading the development ...

    Filing Type:    PU
    MeiraGTx Holdings plc

    MeiraGTx Holdings plc

    We are a vertically integrated, clinical stage gene therapy company with four ongo...

    We are a vertically integrated, clinical stage ...

    Filing Type:    PU
    Semler Scientific, Inc.

    Semler Scientific, Inc.

    Semler Scientific, Inc. is an emerging medical risk-assessment company whose diagn...

    Semler Scientific, Inc. is an emerging medical ...

    Filing Type:    PU
    Biocept, Inc.

    Biocept, Inc.

    Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...

    Biocept, Inc. is a molecular diagnostics compan...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Cytosorbents Corporation

    Cytosorbents Corporation

    CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...

    CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...

    Filing Type:    PU
    Avalon GloboCare Corp.

    Avalon GloboCare Corp.

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...

    Filing Type:    PU
    Galectin Therapeutics Inc.

    Galectin Therapeutics Inc.

    Galectin Therapeutics is a biotechnology company focused on discovery and developm...

    Galectin Therapeutics is a biotechnology compan...

    Filing Type:    PU
    MediciNova, Inc.

    MediciNova, Inc.

    MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...

    MediciNova, Inc. is a publicly-traded biopharma...

    Filing Type:    PU
    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...

    Takeda Pharmaceutical Company Limited (TSE:4502...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.